RARE DISEASE
Staphylococcal scalded skin syndrome
Staphylococcal scalded skin syndrome
Staphylococcal scalded skin syndrome
Synonyms: Generalized exfoliative disease, SSSS
Synonyms: Generalized exfoliative disease, SSSS
Synonyms: Generalized exfoliative disease, SSSS
Drug discovery
1
drug
With orphan designation
Overview
Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated dermatosis caused by exfoliative toxins (ET-A/B) from Staphylococcus aureus, which cleave desmoglein-1 in the epidermis. This results in widespread erythema, painful superficial blistering, and desquamation resembling burns. Primarily affecting children <6 years, it also occurs in adults with immunosuppression or renal impairment. Diagnosis relies on clinical findings, skin biopsy, and toxin detection. Treatment requires prompt systemic antibiotics and supportive wound care to prevent complications like sepsis or dehydration [1][7][11].
Therapies
Antibiotics: IV clindamycin (inhibits toxin production) ± β-lactams (e.g., nafcillin) [3][7].
Supportive care: Fluid resuscitation, pain management, and meticulous skin care (emollients/non-adherent dressings), often in burn/ICU settings [7][11].
Adjuncts: Early debridement of necrotic tissue and monitoring for secondary infections [8][12].
Categories: rare infectious diseases
Research Papers
160 drug discovery papers about Staphylococcal scalded skin syndrome. Recent publications:
160 drug discovery papers about Staphylococcal scalded skin syndrome. Recent publications:
categories:
Small molecules
small molecules
2026-08-06 | Staphylococcal Scalded Skin Syndrome Often Does Not Require Empiric Coverage for Methicillin Resistance.
Staphylococcal scalded skin syndrome (SSSS) requires empiric anti-staphylococcal antibiotic management, selected based on regional rates of resistance. We report a retrospective chart review of the 58 patients diagnosed with SSSS through dermatology consult in our pediatric emergency department between 2015 and 2024. Only one patient had methicillin-resistant bacteria isolated on superficial bacterial culture, despite antibiogram data from our pediatric emergency department demonstrating methicillin resistance in 39.5%-46.8% of overall isolates growing Staphylococcus aureus. When selecting empiric antibiotic management for SSSS, providers should consider that institutional rates of MRSA in SSSS may differ from overall MRSA rates.
2026-06-15 | STAPHYLOCOCCAL SCALDED SKIN SYNDROME ON A 7-YEAR-OLD BOY: A CASE REPORT
Introduction: Staphylococcal Scalded Skin Syndrome often manifests as widespread epidermal peeling caused by staphylococcal exotoxins. It usually presents within 48 hours of birth, is more common in children under 5 years of age and is rare in children older than 6 years. It can manifest with a prodrome of irritability, malaise, fever, and erythematous skin. Case Presentation: This case report presents a 7-year-old boy who came to the hospital with pyrexia as the initial complaint. Two days before admission, erythematous lesions had erupted on his neck, chest, and trunk. Upon hospitalization, physical examination revealed that the lesions had spread to the back and face, with some developing into multiple white pustules, and a positive Nikolsky sign was noted. The patient was treated with maintenance electrolyte fluids at 60 cc/hour, intravenous paracetamol 3×250 mg, intravenous dexamethasone 2×0.3 cc, intravenous cefotaxime 2×500 mg, cetirizine syrup 1×5 ml, and a multivitamin. The skin lesions were managed with wet dressings, followed by application of fusidic acid cream and dexpanthenol cream over all affected areas. Conclusion: The topical regimen was revised on the third day of inpatient care to include fusidic acid cream, desonide 0.05% cream, salicylic acid powder as a keratolytic agent, mometasone furoate 0.1% cream, and pseudo-ceramide lotion 200 ml. Keyword: Staphylococcal Scalded Skin Syndrome; Staphylococcus species; Nikolsky sign; Erythematous skin.
2026-01-28 | Evaluation of lawsone as a potential inhibitor of Staphylococcus aureus efflux pump mediated drugs resistance: An in-vitro and in-silico study.
Staphylococcus aureus (S. aureus) is a causative agent of a wide range of infections such as staphylococcal scalded skin syndrome, toxic shock syndrome, necrotizing pneumonia, endocarditis, and osteomyelitis, posing a significant challenge in clinical management. This study explores the antibacterial potential of lawsone on S. aureus using experimental and computational methods. The minimum inhibitory concentration (MIC) of lawsone (alone and in combination with erythromycin, tetracycline, norfloxacin and ciprofloxacin) on 8 clinical multi-drug resistant S. aureus was evaluated in vitro. The ability of lawsone to modulate antibiotic susceptibility was also determined. Molecular docking was carried out to investigate the binding affinities between lawsone and five efflux pumps (EPP) (NorA, NorB, MsrA, SepA, and MefA) and a ribosomal protection protein (TetM) implicated in S. aureus drug resistance. Furthermore, molecular dynamics simulations (MDS) were performed to assess the stability of the protein-ligand complexes throughout the 100 ns simulation period. In addition, the physicochemical properties, drug-likeness, and toxicity of the lawsone were predicted. Lawsone showed synergistic effects with erythromycin, tetracycline, norfloxacin, and ciprofloxacin, as indicated by the modulation factors (MF) ranging from 2 to > 16. Notably, the strain SA383 showed MF values of > 8 for two antibiotics (ciprofloxacin and erythromycin), and > 16 for norfloxacin. Molecular docking revealed strong binding affinities between lawsone and the evaluated S. aureus drug resistant proteins. The MDS confirmed the stability of the lawsone-protein complexes over 100 ns simulation period, supporting its potential as an efflux pump inhibitor (EPI). ADMET profiling of lawsone demonstrated favorable drug-likeness, pharmacokinetics, and low toxicity. Lawsone does not inhibit major cytochrome P450 enzymes. Toxicity predictions also showed no significant risks of carcinogenicity or immunotoxicity, but potential mutagenicity and nephrotoxicity which require further study. Lawsone also exhibits no predicted activity on androgen receptors, aromatase, or GABA receptors, indicating minimal hormonal disruption. These findings highlight lawsone as a promising candidate for the development of a new EPI candidate, particularly against antibiotic-resistant S. aureus.
2026-01-01 | A Preschool Case of Staphylococcal Scalded Skin Syndrome: Challenges in Recognition and Care
Staphylococcal scalded skin syndrome (SSSS) is a rare, toxin‐mediated dermatosis in children that can mimic bullous impetigo or other severe blistering disorders. We report a 4‐year‐old boy presenting with fever, erythema, painful skin lesions, and conjunctivitis. Initial therapy with intravenous amoxicillin/clavulanic acid was ineffective, and progression to diffuse erythema, desquamation, and a positive Nikolsky sign led to the diagnosis of SSSS. Wound cultures grew Staphylococcus aureus , and escalation to intravenous cloxacillin, combined with supportive care including hydration, analgesia, and skin management, resulted in rapid clinical improvement. The patient was discharged after 10 days with complete recovery and no complications. This case highlights the diagnostic challenge of SSSS and underscores the importance of early recognition and prompt, targeted antistaphylococcal therapy. Supportive management is crucial to prevent serious complications and ensure favorable outcomes in pediatric patients.
2025-12-29 | Case report: Eyelid symptoms as an early harbinger of staphylococcal scalded skin syndrome: a novel pattern of disease onset.
Staphylococcal scalded skin syndrome (SSSS) is a rare but potentially life- threatening condition caused by exfoliative toxin-producing Staphylococcus aureus. Ocular involvement, although infrequently reported, may lead to vision-threatening complications if not promptly recognized. The clinical history, findings, therapy, and outcome of two patients with SSSS exhibiting prominent ocular manifestations at disease onset were analyzed and reported. A comprehensive literature review was performed using PubMed/Medline, Embase, and Scopus incorporating search terms such as "Staphylococcal scalded skin syndrome," "eye," "eyelid," "conjunctival," "ocular manifestations," and "ocular adnexal." Two pediatric patients with SSSS were identified. Case 1: a 4-year-old boy with initial blepharitis progressing to periocular scaling, conjunctival inflammation, and corneal staining, confirmed as SSSS by clinical findings and microbiology. Case 2: a 38-month-old boy presenting with bilateral eyelid edema, periocular desquamation, and perioral lesions, with negative corneal staining. Both patients were treated with systemic antistaphylococcal antibiotics (including toxin-targeting regimens) and topical ocular therapy (fusidic acid gel and hypochlorous acid spray), resulting in rapid clinical improvement and complete resolution of ocular and cutaneous lesions. The literature review identified a single reported case of a healthy adult with purulent conjunctivitis as an initial manifestation of SSSS. Although rare, ocular manifestations may serve as an early indicator of SSSS. Prompt ophthalmological evaluation and combined systemic and targeted topical therapy are essential to prevent ocular sequelae. Awareness of this condition among ophthalmologists and pediatricians is critical to prevent complications and potential permanent visual impairment.
antibodies
2026-02-27 | Erythroderma in the Emergency Department: A Narrative Review
Background/Objectives: Erythroderma is a rare but potentially life-threatening dermatological emergency characterised by generalised erythema and scaling involving more than 80% of the total body surface area. Erythroderma is associated with significant morbidity and mortality due to systemic complications and diverse underlying aetiologies. Methods: In this narrative review PubMed and Google Scholar were searched up to February 2026. Studies were screened for relevance to emergency physicians, with emphasis on epidemiology, diagnostic approach and acute management. Non-English publications and conference abstracts were excluded. Fifty-seven sources were included in the final synthesis. Results: Erythroderma most commonly results from exacerbation of pre-existing inflammatory dermatoses, drug reactions, infections, or cutaneous T-cell lymphoma. Clinical presentation includes diffuse erythema and scaling affecting ≥80–90% of body surface area, often accompanied by pruritus, systemic symptoms, and signs of organ dysfunction. Systemic complications arise from cutaneous barrier failure and include fluid imbalance, thermoregulatory dysfunction, cardiovascular strain, protein loss, and secondary infection. Initial emergency department management prioritises supportive care, fluid and nutritional optimisation, restoration of skin barrier function, and assessment for organ dysfunction. While definitive aetiological diagnosis is not always immediately required, certain conditions—particularly severe drug reactions and infectious causes such as Staphylococcal Scalded Skin Syndrome—necessitate urgent targeted intervention. Conclusions: Erythroderma represents a syndromic emergency requiring systematic evaluation and early supportive management. Prompt recognition of high-risk aetiologies and timely dermatology referral are essential to optimise outcomes and reduce morbidity and mortality.
2025-12-05 | Distinguishing Bacterial vs Viral Rashes in Emergency Settings: A Diagnostic Algorithm for 4th-Year Medical Students.
1. Introduction Rashes are one of the most frequent presenting complaints in emergency medicine, accounting for a significant proportion of pediatric and adult ED visits. For 4th-year medical students and early clinicians, distinguishing between bacterial and viral rashes is a critical skill. The challenge lies in the fact that many exanthems share overlapping features—erythema, papules, fever, and systemic symptoms—yet the underlying causes and management strategies differ dramatically. While most viral rashes are benign, self-limiting, and require only supportive treatment, certain bacterial rashes can progress rapidly, leading to sepsis, multiorgan failure, and death if not quickly identified and treated. Examples include: Meningococcemia, which may initially present with mild fever and subtle petechiae but can progress to shock within hours. Staphylococcal scalded skin syndrome (SSSS), which presents with superficial blistering and skin peeling due to exfoliative toxins. Necrotizing fasciitis, a deep soft tissue infection that may initially resemble simple cellulitis but carries a mortality rate >30%.
2025-07-16 | Staphylococcal Toxiderma in an 18-Month-Old Infant Evolving to Lyell’s Syndrome: A Case Report
Staphylococcal toxidermia is a rare but potentially life-threatening condition in children, occasionally evolving toward a toxic epidermal necrolysis-like presentation (1). Case Presentation: We report the case of an 18-month-old female infant presenting with fever and impetiginous lesions rapidly evolving into a generalized exfoliative eruption suggestive of Lyell’s syndrome. Neurological deterioration was observed. Blood cultures were negative, but the clinical features were compatible with staphylococcal scalded skin syndrome (SSSS). The patient was treated with intravenous vancomycin and a 5-day course of immunoglobulins at 0.4 g/kg/day, resulting in a favorable outcome. Conclusion: This case highlights the importance of early recognition of severe staphylococcal skin syndromes and the potential benefit of adjunctive immunoglobulin therapy in extensive cases with neurological involvement.
2025-03-11 | Staphylococcal scalded skin syndrome
Staphylococcal scalded skin syndrome (SSSS) is an exfoliative dermatosis in which, classically, most of the body surface becomes tender and erythematous and the superficial epidermis strips off. SSSS is caused by epidermolytic toxin A and/or B of certain strains of Staphylococcus aureus , most commonly of phage group II, particularly strains 71 and 55 . These toxins reach the skin via the circulation from a distant focus of infection, usually in the umbilicus, breast, conjunctiva, or the site of circumcision. Neonates are more prone, which is believed to reflect less efficient metabolism and excretion of the toxin. The rapid onset with marked cutaneous tenderness distinguishes it from most of the other causes of erythroderma in infancy. The main differential diagnosis is toxic epidermal necrolysis (TEN), but TEN shows mucosal involvement. Mortality is 2–10% in children with late diagnosis.
2023-09-19 | Comprehensive Analysis of Scalded Skin Syndrome: Clinical Exploration, Underlying Pathophysiology and Advanced Therapeutic Approaches
Scalded skin syndrome, a rare but potentially serious dermatologic entity, stands as a clinical and scientific challenge in the contemporary medical field. This article proposes a comprehensive evaluation of this entity, covering clinical aspects, pathophysiological mechanisms and state-of-the-art therapeutic perspectives. The skin, as the most extensive organ of the human body, is prone to a diversity of pathologies, among which scalded skin syndrome emerges as a condition characterized by significant epidermal exfoliation, commonly evoked by staphylococcal exfoliative toxins. Despite its dramatic clinical presentation, its accurate diagnosis may require meticulous differential evaluation to discern it from other skin conditions with similar manifestations. From a pathophysiological perspective, cutaneous de-adhesion in scalded skin syndrome originates in the specific unbinding of intracellular adhesion molecules, leading to intraepidermal separation and ultimately intraepidermal blistering. The constantly evolving understanding of the molecular processes involved has led to innovative therapeutic approaches that go beyond mere suppression of the causative infection. In this comprehensive review, current and emerging therapeutic options are addressed, including intravenous immunoglobulin, immune response modulating agents, and therapies targeting dysfunctional molecular signaling cascades. In addition, the importance of supportive care and prevention of life-threatening complications, such as sepsis, is discussed. In summary, this article is intended as an essential resource for clinicians, researchers, and healthcare professionals interested in furthering the comprehensive understanding of scalded skin syndrome. The convergence of clinical, basic research, and advanced therapies is crucial to improve early detection, effective management, and prognostic outcomes in this complex dermatologic entity.
proteins
2024-03-01 | Staphylococcal scalded skin syndrome in neonate: Another face of CA-MRSA.
Staphylococcal scalded skin syndrome (SSSS), also known as Ritter's disease, in its severe form occurs predominantly in infants and children. It is caused by infection with group II (often phage group 71) Staphylococcus aureus. The foci of infection include nasopharynx, less commonly umbilicus, urinary tract, superficial abrasion, conjunctivae, and blood. Staphylococci are non-motile, non-spore-forming, catalase-positive, gram-positive cocci that appear predominantly as grape-like clusters. Although this organism is frequently a part of normal human microbial flora, it can cause significant opportunistic infections under certain conditions such as when extremes of age groups are involved, the presence of indwelling medical devices, and intravenous (iv) drug abuse. Staphylococcus aureus may cause a variety of infectious manifestations ranging from relatively benign skin infections to life-threatening systemic illnesses. SSSS caused by S. aureus strains produces exfoliative toxins which result in the development of blisters, erythema, and desquamation. Here, we present a case of an 11-day-old neonate who was diagnosed with SSSS. The causative agent responsible for this syndrome was identified as methicillin-resistant Staphylococcus aureus (MRSA). The molecular characterization of the gene Panton-Valentine leukocidin (PVL) was done by polymerase chain reaction (PCR) and was detected positive for PVL which is a distinctive virulence factor seen almost in all of the community-acquired MRSA strains. The patient was discharged after parenteral clindamycin therapy with almost complete resolution of symptoms.
2021-05-14 | Staphylococcal scalded skin syndrome: An epidemiological and clinical review of 84 cases.
Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated, blistering skin disorder that mainly affects infants and children. There is limited literature regarding pediatric SSSS. The purpose of this study was to describe the epidemiology, clinical features, and management of pediatric SSSS. Retrospective cohort study of pediatric patients with a clinical diagnosis of SSSS seen at the Hospital for Sick Children in Toronto, Ontario, Canada, from January 1994 to March 2016. We included 84 patients with a clinical diagnosis of SSSS; 49/84 (58%) were male. Mean age of diagnosis was 3.1 ± 2.4 years. All patients presented with erythema and exfoliation, while 64/84 (76%) presented with vesicles/ bullae. Skin tenderness was the most common symptom, present in 68/84 (81%) subjects. Staphylococcus aureus was more commonly isolated from periorificial cultures than from bullae. Mean hospitalization was 4.7 ± 2.3 days. No difference was found in admission duration between children receiving clindamycin and those that did not (3.6 ± 2.2 vs 3.9 ± 2.34 days, P = .63). Skin debridement was the only risk factor leading to more complications and prolonged hospitalization (P = .03). Severe complications were seen in 4 (5%) cases, and no fatalities were observed. Healthcare providers should be aware of SSSS and consider it in the differential diagnosis of infants and children with new onset erythema, exfoliation, and/or vesiculation. Suspected culprit pathogens were more often obtained from periorificial swabs; however, these isolates were not tested for exfoliative toxin to confirm causality. Antibiotic treatment should be guided by sensitivity testing. Addition of clindamycin as an anti-toxin agent had no effect on the duration of hospitalization, and this should be further investigated. Surgical debridement of the skin in patients with SSSS should be discouraged.
2020-07-14 | Synergistic antimicrobial activity of melittin with clindamycin on the expression of encoding exfoliative toxin in Staphylococcus aureus.
Staphylococcus aureus is an opportunistic human pathogens, with the ability to produce a series of virulence factors that contribute to the severity of infections. Exfoliative toxins (ETs) are one of the important virulence factors that participating in staphylococcal scalded skin syndrome. Melittin has different biological activities, comprising of antiviral, broad spectrum antibacterial, antiprotozoal, antifungal and anti-inflammatory effects. Twelve clinical isolates of methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) were obtained from wound infection in the burn patients. The MIC plus three sub-inhibitory concentrations (I, II and III) of clindamycin and melittin were tested. Next, the synergistic effects of melittin and clindamycin were evaluated using the broth microdilution checkerboard assay. The detection of exfoliative toxin A and B genes were examined by PCR method. Then the effects of sub-MIC melittin on the expression levels of eta and etb were assessed by quantitative real-time PCR (qRT-PCR) assay. Melittin MIC values against MRSA and MSSA planktonic cells were 0.25-0.5 and 0.25-1 μg/ml, respectively. The clindamycin MIC values against MRSA and MSSA were between 0.5 and 8 μg/ml and 0.5-2 μg/ml, respectively. The results of the time-kill kinetics assay (3.5log10 and 3log10) against MSSA and MRSA planktonic cells were determined within 24 h using melittin. The mean expression of eta in MRSA and MSSA was significantly downregulated to approximately 3.5 and 4 fold, respectively. Moreover, the mean expression of etb in MRSA and MSSA were significantly downregulated to approximately 2.5 and 3 fold, respectively. Hemolytic assay showed that the extracted melittin indicates a strong hemolytic activity (HD50 = 2 μg/ml). Melittin at 0.5 μg/ml induced cell lysis and stimulated the formation of vesicles in S. aureus strains. Melittin could reduce the expression of eta and etb as encoding exfoliative toxin A and B genes. This component appears to be a good candidate for the treatment of MRSA and MSSA strains. So, melittin in combination with clindamycin can be classified as a complementary treatment of wound infections in burn patients.
2006-01-01 | Antimicrobial Properties of α-MSH and Related Synthetic Melanocortins
The natural antimicrobial peptides are ancient host defense effector molecules, present in organisms across the evolutionary spectrum. Several properties of α-melanocyte stimulating hormone (α-MSH) suggested that it could be a natural antimicrobial peptide. α-MSH is a primordial peptide that appeared during the Paleozoic era, long before adaptive immunity developed and, like natural antimicrobial molecules, is produced by barrier epithelia, immunocytes, and within the central nervous system. α-MSH was discovered to have antimicrobial activity against two representative pathogens, Staphylococcus aureus and Candida albicans . The candidacidal influences of α-MSH appeared to be mediated by increases in cell cyclic adenosine monophosphate (cAMP). The cAMP-inducing capacity of α-MSH likely interferes with the yeast's own regulatory mechanisms of this essential signaling pathway. It is remarkable that this mechanism of action in yeast mimics the influences of α-MSH in mammalian cells in which the peptide binds to G-protein-linked melanocortin receptors, activates adenylyl cyclase, and increases cAMP. When considering that most of the natural antimicrobial peptides enhance the local inflammatory reaction, the anti-inflammatory and antipyretic effects of α-MSH confer unique properties to this molecule relative to other natural antimicrobial molecules. Synthetic derivatives, chemically stable and resistant to enzymatic degradation, could form the basis for novel therapies that combine anti-inflammatory and antimicrobial properties.
small molecules
2026-08-06 | Staphylococcal Scalded Skin Syndrome Often Does Not Require Empiric Coverage for Methicillin Resistance.
Staphylococcal scalded skin syndrome (SSSS) requires empiric anti-staphylococcal antibiotic management, selected based on regional rates of resistance. We report a retrospective chart review of the 58 patients diagnosed with SSSS through dermatology consult in our pediatric emergency department between 2015 and 2024. Only one patient had methicillin-resistant bacteria isolated on superficial bacterial culture, despite antibiogram data from our pediatric emergency department demonstrating methicillin resistance in 39.5%-46.8% of overall isolates growing Staphylococcus aureus. When selecting empiric antibiotic management for SSSS, providers should consider that institutional rates of MRSA in SSSS may differ from overall MRSA rates.
2026-06-15 | STAPHYLOCOCCAL SCALDED SKIN SYNDROME ON A 7-YEAR-OLD BOY: A CASE REPORT
Introduction: Staphylococcal Scalded Skin Syndrome often manifests as widespread epidermal peeling caused by staphylococcal exotoxins. It usually presents within 48 hours of birth, is more common in children under 5 years of age and is rare in children older than 6 years. It can manifest with a prodrome of irritability, malaise, fever, and erythematous skin. Case Presentation: This case report presents a 7-year-old boy who came to the hospital with pyrexia as the initial complaint. Two days before admission, erythematous lesions had erupted on his neck, chest, and trunk. Upon hospitalization, physical examination revealed that the lesions had spread to the back and face, with some developing into multiple white pustules, and a positive Nikolsky sign was noted. The patient was treated with maintenance electrolyte fluids at 60 cc/hour, intravenous paracetamol 3×250 mg, intravenous dexamethasone 2×0.3 cc, intravenous cefotaxime 2×500 mg, cetirizine syrup 1×5 ml, and a multivitamin. The skin lesions were managed with wet dressings, followed by application of fusidic acid cream and dexpanthenol cream over all affected areas. Conclusion: The topical regimen was revised on the third day of inpatient care to include fusidic acid cream, desonide 0.05% cream, salicylic acid powder as a keratolytic agent, mometasone furoate 0.1% cream, and pseudo-ceramide lotion 200 ml. Keyword: Staphylococcal Scalded Skin Syndrome; Staphylococcus species; Nikolsky sign; Erythematous skin.
2026-01-28 | Evaluation of lawsone as a potential inhibitor of Staphylococcus aureus efflux pump mediated drugs resistance: An in-vitro and in-silico study.
Staphylococcus aureus (S. aureus) is a causative agent of a wide range of infections such as staphylococcal scalded skin syndrome, toxic shock syndrome, necrotizing pneumonia, endocarditis, and osteomyelitis, posing a significant challenge in clinical management. This study explores the antibacterial potential of lawsone on S. aureus using experimental and computational methods. The minimum inhibitory concentration (MIC) of lawsone (alone and in combination with erythromycin, tetracycline, norfloxacin and ciprofloxacin) on 8 clinical multi-drug resistant S. aureus was evaluated in vitro. The ability of lawsone to modulate antibiotic susceptibility was also determined. Molecular docking was carried out to investigate the binding affinities between lawsone and five efflux pumps (EPP) (NorA, NorB, MsrA, SepA, and MefA) and a ribosomal protection protein (TetM) implicated in S. aureus drug resistance. Furthermore, molecular dynamics simulations (MDS) were performed to assess the stability of the protein-ligand complexes throughout the 100 ns simulation period. In addition, the physicochemical properties, drug-likeness, and toxicity of the lawsone were predicted. Lawsone showed synergistic effects with erythromycin, tetracycline, norfloxacin, and ciprofloxacin, as indicated by the modulation factors (MF) ranging from 2 to > 16. Notably, the strain SA383 showed MF values of > 8 for two antibiotics (ciprofloxacin and erythromycin), and > 16 for norfloxacin. Molecular docking revealed strong binding affinities between lawsone and the evaluated S. aureus drug resistant proteins. The MDS confirmed the stability of the lawsone-protein complexes over 100 ns simulation period, supporting its potential as an efflux pump inhibitor (EPI). ADMET profiling of lawsone demonstrated favorable drug-likeness, pharmacokinetics, and low toxicity. Lawsone does not inhibit major cytochrome P450 enzymes. Toxicity predictions also showed no significant risks of carcinogenicity or immunotoxicity, but potential mutagenicity and nephrotoxicity which require further study. Lawsone also exhibits no predicted activity on androgen receptors, aromatase, or GABA receptors, indicating minimal hormonal disruption. These findings highlight lawsone as a promising candidate for the development of a new EPI candidate, particularly against antibiotic-resistant S. aureus.
2026-01-01 | A Preschool Case of Staphylococcal Scalded Skin Syndrome: Challenges in Recognition and Care
Staphylococcal scalded skin syndrome (SSSS) is a rare, toxin‐mediated dermatosis in children that can mimic bullous impetigo or other severe blistering disorders. We report a 4‐year‐old boy presenting with fever, erythema, painful skin lesions, and conjunctivitis. Initial therapy with intravenous amoxicillin/clavulanic acid was ineffective, and progression to diffuse erythema, desquamation, and a positive Nikolsky sign led to the diagnosis of SSSS. Wound cultures grew Staphylococcus aureus , and escalation to intravenous cloxacillin, combined with supportive care including hydration, analgesia, and skin management, resulted in rapid clinical improvement. The patient was discharged after 10 days with complete recovery and no complications. This case highlights the diagnostic challenge of SSSS and underscores the importance of early recognition and prompt, targeted antistaphylococcal therapy. Supportive management is crucial to prevent serious complications and ensure favorable outcomes in pediatric patients.
2025-12-29 | Case report: Eyelid symptoms as an early harbinger of staphylococcal scalded skin syndrome: a novel pattern of disease onset.
Staphylococcal scalded skin syndrome (SSSS) is a rare but potentially life- threatening condition caused by exfoliative toxin-producing Staphylococcus aureus. Ocular involvement, although infrequently reported, may lead to vision-threatening complications if not promptly recognized. The clinical history, findings, therapy, and outcome of two patients with SSSS exhibiting prominent ocular manifestations at disease onset were analyzed and reported. A comprehensive literature review was performed using PubMed/Medline, Embase, and Scopus incorporating search terms such as "Staphylococcal scalded skin syndrome," "eye," "eyelid," "conjunctival," "ocular manifestations," and "ocular adnexal." Two pediatric patients with SSSS were identified. Case 1: a 4-year-old boy with initial blepharitis progressing to periocular scaling, conjunctival inflammation, and corneal staining, confirmed as SSSS by clinical findings and microbiology. Case 2: a 38-month-old boy presenting with bilateral eyelid edema, periocular desquamation, and perioral lesions, with negative corneal staining. Both patients were treated with systemic antistaphylococcal antibiotics (including toxin-targeting regimens) and topical ocular therapy (fusidic acid gel and hypochlorous acid spray), resulting in rapid clinical improvement and complete resolution of ocular and cutaneous lesions. The literature review identified a single reported case of a healthy adult with purulent conjunctivitis as an initial manifestation of SSSS. Although rare, ocular manifestations may serve as an early indicator of SSSS. Prompt ophthalmological evaluation and combined systemic and targeted topical therapy are essential to prevent ocular sequelae. Awareness of this condition among ophthalmologists and pediatricians is critical to prevent complications and potential permanent visual impairment.
antibodies
2026-02-27 | Erythroderma in the Emergency Department: A Narrative Review
Background/Objectives: Erythroderma is a rare but potentially life-threatening dermatological emergency characterised by generalised erythema and scaling involving more than 80% of the total body surface area. Erythroderma is associated with significant morbidity and mortality due to systemic complications and diverse underlying aetiologies. Methods: In this narrative review PubMed and Google Scholar were searched up to February 2026. Studies were screened for relevance to emergency physicians, with emphasis on epidemiology, diagnostic approach and acute management. Non-English publications and conference abstracts were excluded. Fifty-seven sources were included in the final synthesis. Results: Erythroderma most commonly results from exacerbation of pre-existing inflammatory dermatoses, drug reactions, infections, or cutaneous T-cell lymphoma. Clinical presentation includes diffuse erythema and scaling affecting ≥80–90% of body surface area, often accompanied by pruritus, systemic symptoms, and signs of organ dysfunction. Systemic complications arise from cutaneous barrier failure and include fluid imbalance, thermoregulatory dysfunction, cardiovascular strain, protein loss, and secondary infection. Initial emergency department management prioritises supportive care, fluid and nutritional optimisation, restoration of skin barrier function, and assessment for organ dysfunction. While definitive aetiological diagnosis is not always immediately required, certain conditions—particularly severe drug reactions and infectious causes such as Staphylococcal Scalded Skin Syndrome—necessitate urgent targeted intervention. Conclusions: Erythroderma represents a syndromic emergency requiring systematic evaluation and early supportive management. Prompt recognition of high-risk aetiologies and timely dermatology referral are essential to optimise outcomes and reduce morbidity and mortality.
2025-12-05 | Distinguishing Bacterial vs Viral Rashes in Emergency Settings: A Diagnostic Algorithm for 4th-Year Medical Students.
1. Introduction Rashes are one of the most frequent presenting complaints in emergency medicine, accounting for a significant proportion of pediatric and adult ED visits. For 4th-year medical students and early clinicians, distinguishing between bacterial and viral rashes is a critical skill. The challenge lies in the fact that many exanthems share overlapping features—erythema, papules, fever, and systemic symptoms—yet the underlying causes and management strategies differ dramatically. While most viral rashes are benign, self-limiting, and require only supportive treatment, certain bacterial rashes can progress rapidly, leading to sepsis, multiorgan failure, and death if not quickly identified and treated. Examples include: Meningococcemia, which may initially present with mild fever and subtle petechiae but can progress to shock within hours. Staphylococcal scalded skin syndrome (SSSS), which presents with superficial blistering and skin peeling due to exfoliative toxins. Necrotizing fasciitis, a deep soft tissue infection that may initially resemble simple cellulitis but carries a mortality rate >30%.
2025-07-16 | Staphylococcal Toxiderma in an 18-Month-Old Infant Evolving to Lyell’s Syndrome: A Case Report
Staphylococcal toxidermia is a rare but potentially life-threatening condition in children, occasionally evolving toward a toxic epidermal necrolysis-like presentation (1). Case Presentation: We report the case of an 18-month-old female infant presenting with fever and impetiginous lesions rapidly evolving into a generalized exfoliative eruption suggestive of Lyell’s syndrome. Neurological deterioration was observed. Blood cultures were negative, but the clinical features were compatible with staphylococcal scalded skin syndrome (SSSS). The patient was treated with intravenous vancomycin and a 5-day course of immunoglobulins at 0.4 g/kg/day, resulting in a favorable outcome. Conclusion: This case highlights the importance of early recognition of severe staphylococcal skin syndromes and the potential benefit of adjunctive immunoglobulin therapy in extensive cases with neurological involvement.
2025-03-11 | Staphylococcal scalded skin syndrome
Staphylococcal scalded skin syndrome (SSSS) is an exfoliative dermatosis in which, classically, most of the body surface becomes tender and erythematous and the superficial epidermis strips off. SSSS is caused by epidermolytic toxin A and/or B of certain strains of Staphylococcus aureus , most commonly of phage group II, particularly strains 71 and 55 . These toxins reach the skin via the circulation from a distant focus of infection, usually in the umbilicus, breast, conjunctiva, or the site of circumcision. Neonates are more prone, which is believed to reflect less efficient metabolism and excretion of the toxin. The rapid onset with marked cutaneous tenderness distinguishes it from most of the other causes of erythroderma in infancy. The main differential diagnosis is toxic epidermal necrolysis (TEN), but TEN shows mucosal involvement. Mortality is 2–10% in children with late diagnosis.
2023-09-19 | Comprehensive Analysis of Scalded Skin Syndrome: Clinical Exploration, Underlying Pathophysiology and Advanced Therapeutic Approaches
Scalded skin syndrome, a rare but potentially serious dermatologic entity, stands as a clinical and scientific challenge in the contemporary medical field. This article proposes a comprehensive evaluation of this entity, covering clinical aspects, pathophysiological mechanisms and state-of-the-art therapeutic perspectives. The skin, as the most extensive organ of the human body, is prone to a diversity of pathologies, among which scalded skin syndrome emerges as a condition characterized by significant epidermal exfoliation, commonly evoked by staphylococcal exfoliative toxins. Despite its dramatic clinical presentation, its accurate diagnosis may require meticulous differential evaluation to discern it from other skin conditions with similar manifestations. From a pathophysiological perspective, cutaneous de-adhesion in scalded skin syndrome originates in the specific unbinding of intracellular adhesion molecules, leading to intraepidermal separation and ultimately intraepidermal blistering. The constantly evolving understanding of the molecular processes involved has led to innovative therapeutic approaches that go beyond mere suppression of the causative infection. In this comprehensive review, current and emerging therapeutic options are addressed, including intravenous immunoglobulin, immune response modulating agents, and therapies targeting dysfunctional molecular signaling cascades. In addition, the importance of supportive care and prevention of life-threatening complications, such as sepsis, is discussed. In summary, this article is intended as an essential resource for clinicians, researchers, and healthcare professionals interested in furthering the comprehensive understanding of scalded skin syndrome. The convergence of clinical, basic research, and advanced therapies is crucial to improve early detection, effective management, and prognostic outcomes in this complex dermatologic entity.
proteins
2024-03-01 | Staphylococcal scalded skin syndrome in neonate: Another face of CA-MRSA.
Staphylococcal scalded skin syndrome (SSSS), also known as Ritter's disease, in its severe form occurs predominantly in infants and children. It is caused by infection with group II (often phage group 71) Staphylococcus aureus. The foci of infection include nasopharynx, less commonly umbilicus, urinary tract, superficial abrasion, conjunctivae, and blood. Staphylococci are non-motile, non-spore-forming, catalase-positive, gram-positive cocci that appear predominantly as grape-like clusters. Although this organism is frequently a part of normal human microbial flora, it can cause significant opportunistic infections under certain conditions such as when extremes of age groups are involved, the presence of indwelling medical devices, and intravenous (iv) drug abuse. Staphylococcus aureus may cause a variety of infectious manifestations ranging from relatively benign skin infections to life-threatening systemic illnesses. SSSS caused by S. aureus strains produces exfoliative toxins which result in the development of blisters, erythema, and desquamation. Here, we present a case of an 11-day-old neonate who was diagnosed with SSSS. The causative agent responsible for this syndrome was identified as methicillin-resistant Staphylococcus aureus (MRSA). The molecular characterization of the gene Panton-Valentine leukocidin (PVL) was done by polymerase chain reaction (PCR) and was detected positive for PVL which is a distinctive virulence factor seen almost in all of the community-acquired MRSA strains. The patient was discharged after parenteral clindamycin therapy with almost complete resolution of symptoms.
2021-05-14 | Staphylococcal scalded skin syndrome: An epidemiological and clinical review of 84 cases.
Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated, blistering skin disorder that mainly affects infants and children. There is limited literature regarding pediatric SSSS. The purpose of this study was to describe the epidemiology, clinical features, and management of pediatric SSSS. Retrospective cohort study of pediatric patients with a clinical diagnosis of SSSS seen at the Hospital for Sick Children in Toronto, Ontario, Canada, from January 1994 to March 2016. We included 84 patients with a clinical diagnosis of SSSS; 49/84 (58%) were male. Mean age of diagnosis was 3.1 ± 2.4 years. All patients presented with erythema and exfoliation, while 64/84 (76%) presented with vesicles/ bullae. Skin tenderness was the most common symptom, present in 68/84 (81%) subjects. Staphylococcus aureus was more commonly isolated from periorificial cultures than from bullae. Mean hospitalization was 4.7 ± 2.3 days. No difference was found in admission duration between children receiving clindamycin and those that did not (3.6 ± 2.2 vs 3.9 ± 2.34 days, P = .63). Skin debridement was the only risk factor leading to more complications and prolonged hospitalization (P = .03). Severe complications were seen in 4 (5%) cases, and no fatalities were observed. Healthcare providers should be aware of SSSS and consider it in the differential diagnosis of infants and children with new onset erythema, exfoliation, and/or vesiculation. Suspected culprit pathogens were more often obtained from periorificial swabs; however, these isolates were not tested for exfoliative toxin to confirm causality. Antibiotic treatment should be guided by sensitivity testing. Addition of clindamycin as an anti-toxin agent had no effect on the duration of hospitalization, and this should be further investigated. Surgical debridement of the skin in patients with SSSS should be discouraged.
2020-07-14 | Synergistic antimicrobial activity of melittin with clindamycin on the expression of encoding exfoliative toxin in Staphylococcus aureus.
Staphylococcus aureus is an opportunistic human pathogens, with the ability to produce a series of virulence factors that contribute to the severity of infections. Exfoliative toxins (ETs) are one of the important virulence factors that participating in staphylococcal scalded skin syndrome. Melittin has different biological activities, comprising of antiviral, broad spectrum antibacterial, antiprotozoal, antifungal and anti-inflammatory effects. Twelve clinical isolates of methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) were obtained from wound infection in the burn patients. The MIC plus three sub-inhibitory concentrations (I, II and III) of clindamycin and melittin were tested. Next, the synergistic effects of melittin and clindamycin were evaluated using the broth microdilution checkerboard assay. The detection of exfoliative toxin A and B genes were examined by PCR method. Then the effects of sub-MIC melittin on the expression levels of eta and etb were assessed by quantitative real-time PCR (qRT-PCR) assay. Melittin MIC values against MRSA and MSSA planktonic cells were 0.25-0.5 and 0.25-1 μg/ml, respectively. The clindamycin MIC values against MRSA and MSSA were between 0.5 and 8 μg/ml and 0.5-2 μg/ml, respectively. The results of the time-kill kinetics assay (3.5log10 and 3log10) against MSSA and MRSA planktonic cells were determined within 24 h using melittin. The mean expression of eta in MRSA and MSSA was significantly downregulated to approximately 3.5 and 4 fold, respectively. Moreover, the mean expression of etb in MRSA and MSSA were significantly downregulated to approximately 2.5 and 3 fold, respectively. Hemolytic assay showed that the extracted melittin indicates a strong hemolytic activity (HD50 = 2 μg/ml). Melittin at 0.5 μg/ml induced cell lysis and stimulated the formation of vesicles in S. aureus strains. Melittin could reduce the expression of eta and etb as encoding exfoliative toxin A and B genes. This component appears to be a good candidate for the treatment of MRSA and MSSA strains. So, melittin in combination with clindamycin can be classified as a complementary treatment of wound infections in burn patients.
2006-01-01 | Antimicrobial Properties of α-MSH and Related Synthetic Melanocortins
The natural antimicrobial peptides are ancient host defense effector molecules, present in organisms across the evolutionary spectrum. Several properties of α-melanocyte stimulating hormone (α-MSH) suggested that it could be a natural antimicrobial peptide. α-MSH is a primordial peptide that appeared during the Paleozoic era, long before adaptive immunity developed and, like natural antimicrobial molecules, is produced by barrier epithelia, immunocytes, and within the central nervous system. α-MSH was discovered to have antimicrobial activity against two representative pathogens, Staphylococcus aureus and Candida albicans . The candidacidal influences of α-MSH appeared to be mediated by increases in cell cyclic adenosine monophosphate (cAMP). The cAMP-inducing capacity of α-MSH likely interferes with the yeast's own regulatory mechanisms of this essential signaling pathway. It is remarkable that this mechanism of action in yeast mimics the influences of α-MSH in mammalian cells in which the peptide binds to G-protein-linked melanocortin receptors, activates adenylyl cyclase, and increases cAMP. When considering that most of the natural antimicrobial peptides enhance the local inflammatory reaction, the anti-inflammatory and antipyretic effects of α-MSH confer unique properties to this molecule relative to other natural antimicrobial molecules. Synthetic derivatives, chemically stable and resistant to enzymatic degradation, could form the basis for novel therapies that combine anti-inflammatory and antimicrobial properties.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Staphylococcal scalded skin syndrome.
1 orphan drug designation for Staphylococcal scalded skin syndrome.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Chimeric, humanized monoclonal antibody to staphylococcus | — | FDA | 2000-08-03 | — | Biosynexus, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.